ISCO (International Stem Cell) Tariff Resilience Score: 6/10 (As of Jul. 12, 2026)


ISCO International Stem Cell Corp ISCO
30 GF Score
Price $0.17
GF Value $0.13
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is International Stem Cell Tariff Resilience Score?

International Stem Cell ISCO +3.37% 30 Tariff Resilience Score is 6 as of Jul. 12, 2026. GuruFocus rates ISCO with a GF Score™ of 30/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,370 Biotechnology companies, International Stem Cell ranks better than 75.99% on this metric.

International Stem Cell has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

International Stem Cell has International Stem Cell Corp has moderate tariff exposure due to its international research collaborations and material imports. However, the biotech industry often has tariff exemptions, and the company can adjust its supply chain to mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes International Stem Cell might have Average Resilient.

International Stem Cell  (OTCPK:ISCO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

International Stem Cell Tariff Resilience Score Related Terms

ISCO vs ZVSA, AXIM, HEPA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, International Stem Cell's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

International Stem Cell Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Tariff Resilience Score falls into.


ISCO
30GF Score
International Stem Cell Corp ISCO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
International Stem Cell (ISCO) has a Tariff Resilience Score of 6 as of Jul. 12, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, International Stem Cell ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is International Stem Cell's Tariff Resilience Score too high?
International Stem Cell's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. International Stem Cell's value of 6 is 50% above this industry median. Based on the distribution chart, International Stem Cell ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, International Stem Cell has a GF Score™ of 30/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Tariff Resilience Score compare to ZVSA and AXIM?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #329 out of 1370 companies for Tariff Resilience Score. This places International Stem Cell in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. International Stem Cell's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. International Stem Cell's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. International Stem Cell's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 27.2% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. International Stem Cell's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Tariff Resilience Score is 6 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.17 is trading 27.2% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Modestly Overvalued.

Key valuation signals for ISCO:

  • Tariff Resilience Score: 6
  • GF Value™: $0.13 vs. price of $0.17 (27.2% above fair value)
  • GF Score™: 30/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1370)

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
30GF Score

Get the complete analysis for ISCO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price
$0.13
GF Value